We are live on ! Find out more
ONCY icon

Oncolytics Biotech

21 hedge funds and large institutions have $225K invested in Oncolytics Biotech in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

5% more funds holding

Funds holding: 20 → 21 (+1)

0.89% less ownership

Funds ownership: 2.84% → 1.95% (-0.89%)

66% less capital inflows, than outflows

Capital inflows: $234K | Capital outflows: $697K

Holders
21
Holders Change
+1
Holders Change %
+5%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ONCY Hedge Fund Activity: Q3 2019 in Review

21 of the 4,577 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q3 2019, worth a combined $225K — down 77% from $981K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ONCY positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $149K. The largest seller was Verition Fund Management, exiting entirely with an estimated $695K sold.

  • 21 institutional investors held Oncolytics Biotech (ONCY) as of Q3 2019, up from 20 in Q2 2019.
  • Funds reported $225K of Oncolytics Biotech stock for Q3 2019, down 77% quarter-over-quarter.
  • 3 funds opened new Oncolytics Biotech positions in Q3 2019 and 2 closed out, a net change of +1 holder.
  • The largest Oncolytics Biotech buyer in Q3 2019 was Morgan Stanley, an estimated $149K added.
  • The largest Oncolytics Biotech seller in Q3 2019 was Verition Fund Management, an estimated $695K sold.

Based on aggregated 13F filings for Q3 2019.